 34 AM / in 9 minutes BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics Reuters Staff 
Jan 31 (Reuters) - Seattle Genetics Inc: 
* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE 
* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE 
* DEAL FOR $10.00 PER SHARE IN CASH, OR APPROXIMATELY $614 MILLION. 
* TRANSACTION WAS UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES 
* SEES REVENUE OF $128 MILLION TO $130 MILLION FOR THREE MONTHS ENDED DEC. 31 
* SEATTLE GENETICS- UNDER TERMS OF DEAL, CO WILL COMMENCE TENDER OFFER ON/ABT FEB 8 TO BUY ALL OF OUTSTANDING SHARES OF STOCK OF CASCADIAN THERAPEUTICS 
* SEATTLE GENETICS - ‍IN CONNECTION WITH TRANSACTION, CO HAS SECURED FINANCING COMMITMENT OF $400 MILLION FROM BARCLAYS & JPMORGAN-CHASE BANK​ 
* Q4 REVENUE VIEW $114.2 MILLION -- THOMSON REUTERS I/B/E/S 
* AS OF DECEMBER 31, 2017, SEATTLE GENETICS HAD APPROXIMATELY $413 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Source text for Eikon: Further company coverage: